Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.69 +5.0%	$0.78	$0.38 ▼ $115.57	$7.79M	0.71	1.71 million shs	111,132 shs
FWPAY Forward Pharma A/S	$300.00	$424.38	$1.43 ▼ $5.33	$6M	-42.67	7 shs	11 shs
HILS Hillstream BioPharma	$1.20 -2.8%	$1.54	$0.19 ▼ $2.65	$21.12M	3.08	1.39 million shs	44,549 shs
IBIO iBio	$0.57 -2.3%	$0.77	$0.56 ▼ $6.89	$9.47M	0.6	1.40 million shs	226,046 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-6.60%	-9.18%	-21.83%	+30.74%	-99.12%
FWPAY Forward Pharma A/S	0.00%	0.00%	0.00%	0.00%	0.00%
HILS Hillstream BioPharma	0.00%	-0.48%	-28.67%	-18.28%	-57.81%
IBIO iBio	-1.33%	-7.42%	-28.03%	-26.71%	-62.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	3.4073 of 5 stars	3.5	5.0	0.0	0.0	0.6	1.7	1.9
FWPAY Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBIO iBio	1.1741 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	52,134.47% Upside
FWPAY Forward Pharma A/S	0.00	N/A	N/A	N/A
HILS Hillstream BioPharma	0.00	N/A	N/A	N/A
IBIO iBio	3.00	Buy	$5.00	772.45% Upside

Current Analyst Ratings Breakdown

Latest FWPAY, HILS, IBIO, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
FWPAY Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	$0.48 per share	N/A
IBIO iBio	$375K	25.25	N/A	N/A	$1.41 per share	0.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	$298.12	3.83	N/A	N/A	N/A	N/A	-994.63%	N/A
FWPAY Forward Pharma A/S	-$1.89M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	-$8.47M	-$0.72	N/A	N/A	N/A	N/A	-188.44%	-149.61%	N/A
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
FWPAY Forward Pharma A/S	N/A	N/A	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
FWPAY Forward Pharma A/S	N/A	N/A	N/A
HILS Hillstream BioPharma	N/A	3.01	3.01
IBIO iBio	0.05	1.76	1.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
FWPAY Forward Pharma A/S	2.63%
HILS Hillstream BioPharma	13.36%
IBIO iBio	7.90%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
FWPAY Forward Pharma A/S	71.47%
HILS Hillstream BioPharma	30.24%
IBIO iBio	0.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
FWPAY Forward Pharma A/S	N/A	20,000	7,000	Not Optionable
HILS Hillstream BioPharma	1	17.60 million	12.28 million	Not Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A

FWPAY, HILS, IBIO, and AEON Headlines

Recent News About These Companies

Report details last year's biggest venture deals in Illinois life science companies

August 5, 2025 | chicagobusiness.comC

iBio Faces Nasdaq Delisting Notice for Stock Price

August 1, 2025 | tipranks.com

Pharos IBio Co Ltd Share Price - Investing.com UK

June 30, 2025 | uk.investing.com

iBio Announces Conference Call to Review Myostatin and Activin E Antibody Data and Reveal Third Target in AstralBio Collaboration on June 24 | Nasdaq

June 24, 2025 | nasdaq.com

iBio Advances Obesity Care with Antibody Therapies

June 24, 2025 | tipranks.com

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

June 24, 2025 | globenewswire.com

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

June 23, 2025 | globenewswire.com

iBio Extends Promissory Note Maturity to 2026

June 18, 2025 | tipranks.com

Ibio nominates IBIO-610 as obesity development candidate

June 18, 2025 | bioworld.comB

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

June 16, 2025 | globenewswire.com

Minister hails ‘exciting’ degree where students spend two years working in industry

May 29, 2025 | irishtimes.com

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025 | finance.yahoo.com

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025 | globenewswire.com

iBio, Inc. Reports Strong Q3 2025 Progress

May 4, 2025 | tipranks.com

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

iBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement Transaction

April 30, 2025 | finanznachrichten.de

iBio, Inc. Announces Agreement to Exercise Existing Warrants for $6.2 Million in Gross Proceeds

April 29, 2025 | quiverquant.comQ

iBio Raises $6.2 Million Through Warrant Inducement Transaction

April 29, 2025 | globenewswire.com

iBio Enters Licensing Agreement for Obesity Treatment

April 22, 2025 | tipranks.com

iBio, Inc. Enters Licensing Agreement with AstralBio for First-in-Class Activin E-Targeting Antibody to Address Obesity and Cardiometabolic Diseases

April 22, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

FWPAY, HILS, IBIO, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.69 +0.03 (+4.96%)

Closing price 03:59 PM Eastern

Extended Trading

$0.69 +0.00 (+0.55%)

As of 04:44 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Forward Pharma A/S NASDAQ:FWPAY

Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 2005 and is headquartered in Copenhagen, Denmark.

Hillstream BioPharma NASDAQ:HILS

$1.20 -0.03 (-2.76%)

As of 08/11/2025

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

iBio NYSE:IBIO

$0.57 -0.01 (-2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$0.58 +0.01 (+1.03%)

As of 05:26 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time